Evidence map›Paper›PMID 38664641›Full record

ArticleBMC cancer2024

Effects of reprogrammed splenic CD8

E Skurikhin, N Ermakova, M Zhukova, E Pan, D Widera, L Sandrikina, L Kogai, O Pershina, A Pakhomova, V Yu Pan and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. In Vitro Study of Cancer Stem Cells and Reprogrammed CD3Bulletin of experimental biology and medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

E SkurikhinInstitute of General Pathology and Pathophysiology, 125315, Moscow, Russia. eskurihin@inbox.ru.
N ErmakovaInstitute of General Pathology and Pathophysiology, 125315, Moscow, Russia.
M ZhukovaInstitute of General Pathology and Pathophysiology, 125315, Moscow, Russia. mashazyk@gmail.com.
E PanInstitute of General Pathology and Pathophysiology, 125315, Moscow, Russia.
D WideraStem Cell Biology and Regenerative Medicine Group, School of Pharmacy, Whiteknights Campus, RG6 6AP, Reading, UK.
L SandrikinaGoldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, Lenin, 3, 634028, Tomsk, Russia.
L KogaiGoldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, Lenin, 3, 634028, Tomsk, Russia.
O PershinaGoldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, Lenin, 3, 634028, Tomsk, Russia.
A PakhomovaGoldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Centre of the Russian Academy of Sciences, Lenin, 3, 634028, Tomsk, Russia.
V Yu PanInstitute of General Pathology and Pathophysiology, 125315, Moscow, Russia.
N KushlinskiiBlokhin National Medical Research Center of Oncology, 115522, Moscow, Russia.
A KubatievInstitute of General Pathology and Pathophysiology, 125315, Moscow, Russia.
S MorozovInstitute of General Pathology and Pathophysiology, 125315, Moscow, Russia.
A DygaiInstitute of General Pathology and Pathophysiology, 125315, Moscow, Russia.
Research Institute of General Pathology and Pathophysiology, the Russian Academy of Medical Sciences · RUResearch Institute of Pharmacology and Regenerative Medicine named ED Goldberg · RURussian Academy of Sciences · RUNational Medical Research Center of Cardiology · RUUniversity of Reading · GB

Funding

Ministry of Science and Higher Education Russian Federation 075-15-2020-773
6 · The paper itself

Abstract

backgroundMetastatic disease is a major and difficult-to-treat complication of lung cancer. Considering insufficient effectiveness of existing therapies and taking into account the current problem of lung cancer chemoresistance, it is necessary to continue the development of new treatments.

methodsPreviously, we have demonstrated the antitumor effects of reprogrammed CD8

resultsThe present study has indicated that the reprogramming procedure enhances the survival and cytotoxicity of splenic CD8

conclusionsOur proposed reprogramming method enhances the antitumor activity of CD8

Indexed as

Carcinoma, Lewis LungCD8-Positive T-LymphocytesSpleenAnimalsCell Line, TumorCellular ReprogrammingDisease Models, AnimalLung NeoplasmsMiceMice, Inbred C57BLCell therapyLewis lung carcinomaLung cancerMetastatic diseaseReprogrammed spleen CD8+ T-cells

Identifiers

PMID38664641
PMCPMC11046928
OpenAlexW4395465074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.